• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 10:02:33 AM ET
    $NVIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $NVIV alert in real time by email
    SC 13G/A 1 tm216476d40_sc13ga.htm SC 13G/A

     

     

     

    CUSIP No: 46186M506

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2.

     

    (Amendment No. 1)*

     

    InVivo Therapeutics Holdings Corp.

    (Name of Issuer)

     

    Common Stock, $0.00001 par value per share

    (Title of Class of Securities)

     

    46186M506

    (CUSIP Number)

     

    December 31, 2020

    (Date of Event Which Requires Filing of this statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)
    xRule 13d-1(c)
    ¨Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No: 46186M506

     

    (1) NAMES OF REPORTING PERSONS
     
      CVI Investments, Inc.
     
    (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
      (SEE INSTRUCTIONS)
      (a)       ¨
      (b)       ¨
     
    (3) SEC USE ONLY
     
    (4) CITIZENSHIP OR PLACE OF ORGANIZATION
     
      Cayman Islands

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

     

      (5) SOLE VOTING POWER
         
        0
         
      (6) SHARED VOTING POWER **
         
       

    1,018,701

         
         
      (7) SOLE DISPOSITIVE POWER
         
        0
         
      (8) SHARED DISPOSITIVE POWER **
         
        1,018,701

     

    (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
       

    1,018,701

       
    (10) CHECK BOX IF THE AGGREGATE AMOUNT
      IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      ¨
    (11) PERCENT OF CLASS REPRESENTED
      BY AMOUNT IN ROW (9)
     
        4.8%
       
    (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      CO
       

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No: 46186M506

     

    (1) NAMES OF REPORTING PERSONS
     
      Heights Capital Management, Inc.
     
    (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
      (SEE INSTRUCTIONS)
      (a)       ¨
      (b)       ¨
     
    (3) SEC USE ONLY
     
    (4) CITIZENSHIP OR PLACE OF ORGANIZATION
     
      Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

     

      (5) SOLE VOTING POWER
         
        0
         
      (6) SHARED VOTING POWER **
         
        1,018,701
         
         
      (7) SOLE DISPOSITIVE POWER
         
        0
         
      (8) SHARED DISPOSITIVE POWER **
         
        1,018,701

     

    (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
       

    1,018,701

       
    (10) CHECK BOX IF THE AGGREGATE AMOUNT
      IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      ¨
    (11) PERCENT OF CLASS REPRESENTED
      BY AMOUNT IN ROW (9)
     
        4.8%
       
    (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      CO
       

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No: 46186M506

     

    Item 1.

     

    (a)Name of Issuer

     

    InVivo Therapeutics Holdings Corp. (the “Company”)

     

    (b)Address of Issuer’s Principal Executive Offices

     

    One Kendall Square, Suite B14402, Cambridge, MA 02139

     

    Item 2(a).Name of Person Filing

     

    This statement is filed by the entities listed below, who are collectively referred to herein as “Reporting Persons,” with respect to the shares of common stock of the Company, $0.00001 par value per share (the “Shares”).

     

    (i)CVI Investments, Inc.

     

    (ii)Heights Capital Management, Inc.

     

    Item 2(b).Address of Principal Business Office or, if none, Residence

     

    The address of the principal business office of CVI Investments, Inc. is:

     

    P.O. Box 309GT 

    Ugland House

    South Church Street

    George Town

    Grand Cayman

    KY1-1104 

    Cayman Islands

     

    The address of the principal business office of Heights Capital Management, Inc. is:

     

    101 California Street, Suite 3250 

    San Francisco, California 94111

     

    Item 2(c).Citizenship

     

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Item 2(d)Title of Class of Securities

     

    Common stock, $0.00001 par value per share

     

    Item 2(e)CUSIP Number

     

    46186M506

     

     

     

     

    CUSIP No: 46186M506

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
         
    (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
         
    (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
         
    (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
         
    (e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
         
    (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
         
    (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
         
    (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ________________

     

    Item 4. Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    The number of Shares reported as beneficially owned consists of Shares issuable upon the exercise of warrants to purchase Shares.

     

    The Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020 indicates there were 21,171,836 Shares outstanding as of November 2, 2020.

     

    Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

     

     

     

     

    CUSIP No: 46186M506

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certification

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

       

     

     

    CUSIP No: 46186M506

     

    SIGNATURES

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

     

    Dated: February 10, 2021

     

    CVI INVESTMENTS, INC. HEIGHTS CAPITAL MANAGEMENT, INC.
       
    By: Heights Capital Management, Inc. By: /s/ Brian Sopinsky
    pursuant to a Limited Power of Name: Brian Sopinsky
    Attorney, a copy of which was Title: Secretary
    previously filed    

     

    By: /s/ Brian Sopinsky  
    Name: Brian Sopinsky  
    Title: Secretary  

     

       

     

     

    CUSIP No: 46186M506

    EXHIBIT INDEX

     

    EXHIBIT   DESCRIPTION
    I   Limited Power of Attorney*
    II   Joint Filing Agreement*
         

     

    *Previously filed

     

     

     

    Get the next $NVIV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NVIV

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NVIV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Foose Brice closing all direct ownership in the company (SEC Form 4)

    4 - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Issuer)

    2/7/24 1:31:40 PM ET
    $NVIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NVIV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    InVivo Therapeutics Announces Topline Data from Pivotal INSPIRE 2.0 Study in Acute Spinal Cord Injury

    Study did not achieve primary endpoint of defined improvement on standard impairment scale InVivo to evaluate full data set and strategic options for the company InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries (SCI), today announced topline results from the company's INSPIRE 2.0 study, which was designed to evaluate the safety and probable benefit of InVivo's investigational Neuro-Spinal Scaffold™, a bioresorbable scaffold-based device in development for patients with acute SCI. The study did not meet its primary endpoint, which was assessed by the proportion of tre

    3/9/23 8:55:00 AM ET
    $NVIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    InVivo Therapeutics Announces Closing of $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules

    InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has closed its previously announced registered direct offering for the sale and issuance of 154,000 shares of the Company's common stock and pre-funded warrants to purchase up to 369,810 shares of common stock to a single healthcare-focused institutional investor. The Company also closed its previously announced private placement priced at-the-market under Nasdaq rules for the sale and issuance of pre-funded warrants to purchase up to 1,190,476 shares of common stock with the same investor in the

    10/11/22 4:01:00 PM ET
    $NVIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    InVivo Therapeutics Announces $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules

    InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the sale and issuance of 523,810 shares of the Company's common stock (or pre-funded warrants in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq rules. Concurrently with the registered direct offering, the Company entered into a definitive agreement with the investor in the registered direct offering for the sale and issuance of 1,190,476 shares of common stock (or

    10/7/22 8:00:00 AM ET
    $NVIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NVIV
    SEC Filings

    View All

    InVivo Therapeutics Holdings Corp filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Filer)

    2/6/24 8:00:33 AM ET
    $NVIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    InVivo Therapeutics Holdings Corp filed SEC Form 8-K: Bankruptcy or Receivership

    8-K - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Filer)

    2/1/24 8:00:41 AM ET
    $NVIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    InVivo Therapeutics Holdings Corp filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Filer)

    1/3/24 4:30:44 PM ET
    $NVIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NVIV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Foose Brice sold $123,030 worth of InVivo Therapeutics Holdings Corp (330,000 units at $0.37), closing all direct ownership in the company (SEC Form 4) (Amendment)

    4/A - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Issuer)

    2/7/24 2:12:16 PM ET
    $NVIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Foose Brice closing all direct ownership in the company (SEC Form 4)

    4 - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Issuer)

    2/7/24 1:31:40 PM ET
    $NVIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3: New insider Foose Brice claimed ownership of 330,000 units of InVivo Therapeutics Holdings Corp

    3 - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Issuer)

    4/24/23 3:26:07 PM ET
    $NVIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NVIV
    Leadership Updates

    Live Leadership Updates

    View All

    InVivo Therapeutics Announces Appointment of Heather M. Hamel as Chief Legal Officer and General Counsel

    InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced the appointment of Heather M. Hamel, J.D. as its Chief Legal Officer and General Counsel. In her role, Ms. Hamel will lead the company's legal and intellectual property functions, and provide strategic guidance to the company's Board of Directors and executive management team. Ms. Hamel will also be responsible for the oversight of certain other functions, including business development, human resources and external communications. Prior to this appointment, Ms. Hamel served as the company's Vice Preside

    7/13/22 8:30:00 AM ET
    $NVIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NVIV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by InVivo Therapeutics Holdings Corp (Amendment)

    SC 13G/A - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Subject)

    2/14/24 2:53:34 PM ET
    $NVIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by InVivo Therapeutics Holdings Corp (Amendment)

    SC 13G/A - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Subject)

    2/13/24 8:09:46 PM ET
    $NVIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by InVivo Therapeutics Holdings Corp (Amendment)

    SC 13G/A - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Subject)

    2/6/24 12:08:03 PM ET
    $NVIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care